A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis2018-01-17T17:00:50-05:00
Accumulation of irreversible disability in multiple sclerosis: From epidemiology to treatment Accumulation of irreversible disability in multiple sclerosis: From epidemiology to treatment2018-01-17T17:00:50-05:00
Prevalence of Vitamin D Deficiency Among Healthy Adolescents Prevalence of Vitamin D Deficiency Among Healthy Adolescents2018-01-17T17:00:45-05:00
An array of possibilities for the study of autoimmunity An array of possibilities for the study of autoimmunity2018-01-17T17:00:38-05:00
Dietary intake of n-3, n-6 fatty acids and fish: Relationship with hostility in young adultsFthe CARDIA study Dietary intake of n-3, n-6 fatty acids and fish: Relationship with hostility in young adultsFthe CARDIA study2018-01-17T17:00:38-05:00
Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2R -targeted therapy (daclizumab) in multiple sclerosis Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2R -targeted therapy (daclizumab) in multiple sclerosis2018-01-17T17:00:33-05:00
1α,25-dihydroxyvitamin D3 inhibits prostate cancer cell invasion via modulation of selective proteases 1α,25-dihydroxyvitamin D3 inhibits prostate cancer cell invasion via modulation of selective proteases2018-01-17T17:00:33-05:00
Vitamin D and Autoimmune Disease— Implications for Practice from the Multiple Sclerosis Literature Vitamin D and Autoimmune Disease— Implications for Practice from the Multiple Sclerosis Literature2018-01-17T17:00:25-05:00
Genomic Effects of IFN- in Multiple Sclerosis Patients Genomic Effects of IFN- in Multiple Sclerosis Patients2018-01-17T17:00:25-05:00